Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 289-298

  Eurich, Dennis ^a   Boas Knoop, Sabine ^a   Ruehl, Martin ^a   Schulz, Maria ^a   Carrillo, Esperanza D ^a   Berg, Thomas ^b   Neuhaus, Ruth ^a   Neuhaus, Peter ^a   Neumann, Ulf Peter ^a   Bahra, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMANTADINE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SILIBININ;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BIOCHEMISTRY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT DYSFUNCTION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952417218     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22235     Document Type: Article

References (51)

1. Rossol S., Chronic HCV infections. A model disease for therapy, economics and social-medical aspects [in German]. Gesundheitswesen 2007; 69: 146-150. (Pubitemid 46724267)
2. Iadonato SP, Katze MG., Genomics: hepatitis C virus gets personal. Nature 2009; 461: 357-358.
3. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P,. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231. (Pubitemid 38155751)
4. Berenguer M., Recurrent allograft disease: viral hepatitis. Acta Gastroenterol Belg 2005; 68: 337-346. (Pubitemid 41474743)
5. Berenguer M, Prieto M, Palau A, Rayon JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-235. (Pubitemid 36322323)
6. Prieto M, Berenguer M, Rimola A, Loinaz C, Barrios C, Clemente G, et al. Liver transplantation in hepatitis C. A Spanish multi-centre experience. Eur J Gastroenterol Hepatol 1998; 10: 771-776. (Pubitemid 28493187)
7. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836. (Pubitemid 39434314)
8. Burra P., Hepatitis C., Semin Liver Dis 2009; 29: 53-65.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
10. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. HEPATOLOGY 2002; 36 (4 pt 1): 967-972.
11. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567.
12. Terrault NA, Berenguer M., Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204. (Pubitemid 44194586)
13. Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci 2010; 55: 2063-2069.
14. Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, Neuhaus P,. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43-47. (Pubitemid 44296976)
15. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK,. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21 (1 pt 2): 275-280.
16. Schuppan D, Krebs A, Bauer M, Hahn EG., Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (suppl 1): S59-S67. (Pubitemid 36511853)
17. Friedman SL., Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105. (Pubitemid 40823677)
18. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-789.
19. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777.
20. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
21. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. HEPATOLOGY 1999; 29: 250-256. (Pubitemid 29024010)
22. Shuhart MC, Bronner MP, Gretch DR, Thomassen LV, Wartelle CF, Tateyama H, et al. Histological and clinical outcome after liver transplantation for hepatitis C. HEPATOLOGY 1997; 26: 1646-1652. (Pubitemid 27520036)
23. Everson GT., Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8 (10 suppl 1): S19-S27. (Pubitemid 35154039)
24. Shackel NA, Jamias J, Rahman W, Prakoso E, Strasser SI, Koorey DJ, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15: 709-718.
25. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. HEPATOLOGY 2000; 31: 828-833. (Pubitemid 30169926)
26. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Laundy GJ., Human cytokine gene nucleotide sequence alignments, 1998. Eur J Immunogenet 1998; 25: 83-265. (Pubitemid 28195973)
27. Bataller R., Genetic polymorphisms and liver diseases [in Spanish]. Gastroenterol Hepatol 2003; 26: 307-309. (Pubitemid 36723400)
28. Wasmuth HE, Lammert F, Matern S., Genetic risk factors for hepatic fibrosis in chronic liver diseases [in German]. Med Klin (Munich) 2003; 98: 754-762. (Pubitemid 38029674)
29. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
31. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
32. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
33. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
34. Robek MD, Boyd BS, Chisari FV., Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854. (Pubitemid 40327973)
35. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM,. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898. (Pubitemid 44958521)
36. Li M, Liu X, Zhou Y, Su SB., Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
37. Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, Ramadori G,. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004; 84: 1148-1159. (Pubitemid 39128260)
38. Banff schema for grading liver allograft rejection: an international consensus document. HEPATOLOGY 1997; 25: 658-663.
39. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ., Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513-1520. (Pubitemid 24166476)
40. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, Patel N,. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649-654. (Pubitemid 26373881)
41. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7-14. (Pubitemid 38780932)
42. Ben-Ari Z., Role of cytokine gene polymorphism in recurrent HCV infection after liver transplantation. Liver Transpl 2006; 12: 1723-1724. (Pubitemid 44742560)
43. Toniutto P, Fabris C, Falleti E, Cussigh A, Fontanini E, Bitetto D, et al. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. Liver Int 2008; 28: 257-263. (Pubitemid 351201039)
44. Eid AJ, Brown RA, Paya CV, Razonable RR., Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84: 511-516. (Pubitemid 47312163)
45. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68. (Pubitemid 36104710)
46. Sommereyns C, Paul S, Staeheli P, Michiels T., IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
47. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456. (Pubitemid 30484478)
48. Berenguer M., Natural history of recurrent hepatitis C. Liver Transpl 2002; 8 (10 suppl 1): S14-S18. (Pubitemid 35154038)
49. Moroso V, Metselaar HJ, Mancham S, Tilanus HW, Eissens D, van der Meer A, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16: 895-908.
50. Banasch M, Emminghaus R, Ellrichmann M, Schmidt WE, Goetze O., Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test. Aliment Pharmacol Ther 2008; 28: 443-449. (Pubitemid 352033277)
51. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA,. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375. (Pubitemid 34116988)